Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lexicon Appoints Mike Exton As New Chief Executive Officer And Director Succeeding Lonnel Coats Who, As Previously Announced, Retired Effective July 7, 2024

Author: Benzinga Newsdesk | July 08, 2024 09:21am

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis.

Posted In: LXRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist